Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Sertraline. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 known ✓ | P31645 | 5/20 | 1.00 |
| ▸ | MEN1 | O00255 | 5/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 5/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 5/20 | 1.00 |
| ▸ | SLC6A2 | P23975 | 5/20 | 1.00 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 3/20 | 1.00 |
| ▸ | NPC1 | O15118 | 2/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 2/20 | 1.00 |
| ▸ | MTOR | P42345 | 2/20 | 1.00 |
| ▸ | RAB9A | P51151 | 2/20 | 1.00 |
| ▸ | MLNR | O43193 | 1/20 | 1.00 |
| ▸ | NR1I2 | O75469 | 1/20 | 1.00 |
| ▸ | ABCB11 | O95342 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
| ▸ | CHRM4 | P08173 | 1/20 | 1.00 |
| ▸ | ABCB1 | P08183 | 1/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sertraline SCHEMBL29690831 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3841967 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL14028076 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3885286 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL7922153 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3947169 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL30244837 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL3856872 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL137619 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 | |
| Sertraline SCHEMBL137618 | 1.00 | MEN1 (1.00) | MEN1KMT2ACYP3A4SLC6A2SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3607938-B1 | PHARMACEUTICAL COMPOSITION | SOVIC BRKICIC LJILJANA (HR) | 2026-05-27 | — | — | EP | claimed |
| EP-3713986-B1 | COMPOSITION | REBIO TECH OY (FI) | 2026-04-01 | — | — | EP | claimed |
| EP-4209246-B1 | METHOD OF MANUFACTURING OF A PARTICLE-ATTACHED MICRONEEDLE | QUADMEDICINE INC (KR) | 2026-02-18 | — | — | EP | claimed |
| EP-3507371-B1 | COMPOSITIONS FOR TREATING DISEASES AND DISORDERS OF THE NERVOUS SYSTEM | UNIV RUTGERS (US) | 2026-01-28 | — | — | EP | claimed |
| EP-3931189-B1 | AZEPINO-INDOLES AND OTHER HETEROCYCLES FOR TREATING BRAIN DISORDERS | UNIV CALIFORNIA (US) | 2025-12-24 | — | — | EP | claimed |
| EP-4208466-B1 | HIGH AFFINITY MACROCYCLIC FKB51-INHIBITORS FOR TREATMENT OF PSYCHIATRIC DISORDERS | UNIV DARMSTADT TECH (DE) | 2025-06-11 | — | — | EP | claimed |
| EP-3603674-B1 | COMBINATION OF MORPHINAN COMPOUNDS AND ANTIDEPRESSANT FOR THE TREATMENT OF INTRACTABLE AND CHRONIC PAIN | SUN PHARMACEUTICAL IND INC (US) | 2025-02-26 | — | — | EP | claimed |
| EP-3946296-B9 | EXTENDED RELEASE PHARMACEUTICAL FORMULATION | DOUGLAS PHARMACEUTICALS LTD (NZ) | 2024-12-25 | — | — | EP | claimed |
| EP-3294337-B1 | TREATMENT OF DEBILITATING FATIGUE BY COMBINED USE OF 3(S)-3-[3-(METHYLSULFONYL)PHENYL]-1- PROPYLPIPERIDINE AND AN ANTI-DEPRESSIVE AGENT | ARVID CARLSSON RES AB (SE) | 2024-12-18 | — | — | EP | claimed |
| EP-4023222-B1 | NONSELECTIVE METABOTROPIC GLUTAMATE RECEPTOR ACTIVATOR FOR TREATMENT OF 22Q SYNDROME | CHILDRENS HOSPITAL PHILADELPHIA (US) | 2024-12-18 | — | — | EP | claimed |
| EP-3151837-B1 | PROTECTIVE EFFECT OF DMPC, DMPG, DMPC/DMPG, EGPG, LYSOPG AND LYSOPC AGAINST DRUGS THAT CAUSE CHANNELOPATHIES | SIGNPATH PHARMA INC (US) | 2023-03-15 | — | — | EP | claimed |
| WO-2022173841-A9 | METHODS OF MODELING IN VIVO EFFICACY OF DRUG COMBINATIONS FOR TREATMENT OF VIRAL INFECTIONS | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2023-03-02 | — | — | WO | claimed |
| EP-4139929-A1 | METHOD FOR PROVIDING A MEDICATION COMBINATION AND DATA CARRIER WITH SOFTWARE | Universität Ulm (DE) | 2023-03-01 | — | — | EP | claimed |
| EP-3891505-B1 | A METHOD FOR MEASURING A CONCENTRATION OF A BIOMARKER/ANALYTE IN BLOOD FROM MAMMALS | REDHOTDIAGNOSTICS AB (SE) | 2022-11-30 | — | — | EP | claimed |
| EP-3337456-B1 | LIPOSOMES WITH GINSENOSIDE AS MEMBRANE MATERIAL AND PREPARATIONS AND USE THEREOF | SHANGHAI GINPOSOME PHARMATECH CO LTD (CN) | 2022-10-26 | — | — | EP | claimed |
| EP-4057999-A1 | PROCESS FOR PREPARING NANO- OR MICROPARTICLES COMPRISING A CARRIER-POLYMER AND ONE OR MORE BIOLOGICALLY ACTIVE INGREDIENTS | Evonik Operations GmbH (DE) | 2022-09-21 | — | — | EP | claimed |
| EP-3071194-B1 | PHARMACOLOGICAL TREATMENT OF OBSESSIVE-COMPULSIVE DISORDER USING STIRIPENTOL OR A SIMILAR COMPOUND | BIOCODEX (FR) | 2022-08-03 | — | — | EP | claimed |
| EP-3583076-B1 | ENZYMATIC PURIFICATION OF TOILET WATER | PHAREM BIOTECH AB (SE) | 2022-06-29 | — | — | EP | claimed |
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3454853-B1 | TREATMENT OF ALCOHOLISM AND DEPRESSION USING IBUDILAST | MEDICINOVA INC (US) | 2022-05-18 | — | — | EP | claimed |